H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Esperion today and set a price target of $16.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Esperion’s strategic advancements and potential for growth. One of the primary reasons is the nomination of ESP-2001 as a preclinical candidate for treating Primary Sclerosing Cholangitis (PSC). This development leverages Esperion’s expertise in ACLY therapy and collaboration with Evotec, showcasing promising preclinical results in reducing inflammation and fibrosis markers, with a First-in-Human trial expected in 2026. This marks a significant milestone in expanding Esperion’s pipeline into new therapeutic areas.
Additionally, Esperion’s strategic legal settlements with multiple companies, including Dr. Reddy’s Laboratories, ensure market exclusivity for NEXLETOL and NEXLIZET until 2040, which strengthens its market position. Furthermore, the regulatory approval of NEXLETOL in Japan by Otsuka Pharmaceuticals represents a critical milestone in Esperion’s commercial expansion. The approval, coupled with favorable trial results and the potential for milestone payments and royalties, underscores Esperion’s growth prospects in major global markets.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Capricor Therapeutics, and Astria Therapeutics. According to TipRanks, Pantginis has an average return of 2.0% and a 44.72% success rate on recommended stocks.